Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer
View abstract on PubMed
Summary
This summary is machine-generated.Salivary transcriptomic biomarkers show promise for early pancreatic cancer detection. A panel of four messenger RNA biomarkers demonstrated high sensitivity and specificity in distinguishing cancer patients from controls.
Area Of Science
- Oncology
- Biomarker Discovery
- Translational Medicine
Background
- Early detection of pancreatic cancer remains a significant clinical challenge, often leading to diagnosis at an incurable stage.
- Current diagnostic methods lack sufficient sensitivity and specificity for early-stage pancreatic cancer detection.
- Novel strategies and biomarkers are urgently needed for noninvasive early diagnosis.
Purpose Of The Study
- To evaluate the performance and translational utility of salivary transcriptomic biomarkers for noninvasive detection of resectable pancreatic cancer.
- To identify and validate specific messenger RNA (mRNA) biomarkers in saliva for pancreatic cancer diagnosis.
- To establish a proof of concept for salivary biomarkers in systemic cancer detection.
Main Methods
- Prospective sample collection followed by retrospective blinded validation.
- Transcriptomic profiling of saliva supernatant using Affymetrix HG U133 Plus 2.0 Array to identify differentially expressed genes.
- Clinical validation of discovered biomarkers in an independent cohort comprising pancreatic cancer patients, chronic pancreatitis patients, and healthy controls.
Main Results
- Twelve mRNA biomarkers were identified and validated.
- A logistic regression model combining four mRNA biomarkers (KRAS, MBD3L2, ACRV1, and DPM1) achieved an area under the curve (AUC) of 0.971.
- This panel demonstrated high diagnostic accuracy with 90.0% sensitivity and 95.0% specificity in differentiating pancreatic cancer patients from noncancer subjects.
Conclusions
- Salivary transcriptomic biomarkers exhibit significant discriminatory power for detecting resectable pancreatic cancer.
- The validated biomarker panel offers high specificity and sensitivity for noninvasive pancreatic cancer diagnosis.
- This study provides foundational evidence for salivary biomarkers in systemic cancer detection, paving the way for further clinical validation.